Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 3/2005

01-10-2005

Arsenic Trioxide Therapy in Relapsed or Refractory Japanese Patients with Acute Promyelocytic Leukemia: Updated Outcomes of the Phase II Study and Postremission Therapies

Authors: Kazuyuki Shigeno, Kensuke Naito, Naohi Sahara, Miki Kobayashi, Satoki Nakamura, Sinya Fujisawa, Kaori Shinjo, Akihiro Takeshita, Ryuzo Ohno, Kazunori Ohnishi

Published in: International Journal of Hematology | Issue 3/2005

Login to get access
Metadata
Title
Arsenic Trioxide Therapy in Relapsed or Refractory Japanese Patients with Acute Promyelocytic Leukemia: Updated Outcomes of the Phase II Study and Postremission Therapies
Authors
Kazuyuki Shigeno
Kensuke Naito
Naohi Sahara
Miki Kobayashi
Satoki Nakamura
Sinya Fujisawa
Kaori Shinjo
Akihiro Takeshita
Ryuzo Ohno
Kazunori Ohnishi
Publication date
01-10-2005
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 3/2005
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1532/IJH97.05044

Other articles of this Issue 3/2005

International Journal of Hematology 3/2005 Go to the issue

Letter to the Editor

Nephrotic Syndrome with Extensive Mesangiolysis as a Clinical Manifestation of Chronic Graft-versus-Host Disease (GVHD)

OriginalPaper

Combination Therapy with Thalidomide, Incadronate, and Dexamethasone for Relapsed or Refractory Multiple Myeloma

OriginalPaper

Economic Evaluation of Intravenous Itraconazole for Presumed Systemic Fungal Infections in Neutropenic Patients in Korea

OriginalPaper

Dyskeratosis Congenita: A Disorder of Defective Telomere Maintenance?

OriginalPaper

Hepatitis C Virus Infection in Adult Chinese Hemophilia Patients Negative for the Human Immunodeficiency Virus: Treatment Results with Interferon and Ribavirin

Case Report

Cicatricial Pemphigoid of the Oropharynx after Allogeneic Stem Cell Transplantation for Relapsed Follicular Lymphoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits